– January 1, 2006
January 1, 2006
View Issues
-
Pharmacology Watch
-
Clinical Briefs in Primary Care supplement
-
Transplant Response May Not Benefit Myeloma
The results of this study show that HDT intensification, when given to myeloma patients who have responded to the initial chemotherapy, significantly increases the CR rate but has no significant impact on PFS or OS. -
Darbepoetin Alfa for the Treatment of Anemic Patients with Low- and Intermediate-1-Risk Myelodysplastic Syndromes
In a clinical trial of darbepoetin alfa for patients with low or intermediate risk myelodysplasia, the drug was well tolerated and resulted in improved hemoglobin levels and quality of life in a substantial proportion of patients. -
Low-Income Women, Breast and Gynecologic Cancer, and Depression and Anxiety
Because these women are unlikely to receive depression treatment or supportive counseling, there is a need for routine screening, evaluation, and treatment in this population. -
TLK286 Demonstrates Activity in Platinum and Paclitaxel Resistant and Refractory Ovarian Cancer
TLK286 is an active agent in chemotherapy-resistant ovarian cancer. Further studies of TLK286 in platinum and paclitaxel refractory or resistant ovarian cancer are in progress. -
Pharmacology Update: Nelarabine Injection (Arranon®)
The FDA has approved nelarabine for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic leukemia (T-LBL). Nelarabine was approved under the FDAs accelerated approval program. It received an Orphan Designation because it is for a rare disease affecting less than 200,000 in the United States. Nelarabine is marketed by GlaxoSmithKline as Arranon®.